More than two dozen clinical researchers from Roswell Park Comprehensive Cancer Center will be among the more than 30,000 cancer specialists gathered in Chicago for the American Society of Clinical Oncology (ASCO) 51st Annual Meeting. Several teams will be presenting the findings of Roswell Park-led research to their colleagues from around the world.
Two Roswell Park studies will be featured in poster discussion sessions during the meeting: a study reporting the results of a phase III study of the drug lenalidomide in patients with multiple myeloma and a biomarker analysis of squamous-cell anal tumors that revealed several potential targets. Other highlights include a study on the novel agent entolimod in several solid-tumor cancers; a report on a mobile application developed at Roswell Park to predict post-operative survival in patients who undergo surgery to remove colorectal tumors; and a database analysis that revealed a striking increase in melanoma incidence over the last four decades.
Additionally, members of the media interested in learning more about Roswell Park’s studies presented at ASCO 2015, or in need of an expert for comment on another study, should contact Annie Deck-Miller, who will be onsite at the meeting, at annie.deck-miller@roswellpark.org or Deborah Pettibone at Roswell Park, at deborah.pettibone@roswellpark.org.
ASCO 2015 will be held in McCormick Place, Chicago, Ill., from May 29 to June 2, 2015. Founded in 1964, ASCO is the world’s leading professional organization representing physicians who care for people with cancer.
Onsite Contact
Annie Deck-Miller, Senior Media Relations Manager
716-602-5817 (mobile); annie.deck-miller@roswellpark.org
Buffalo Contact
Deborah Pettibone, Public Information Specialist
716-845-4919; deborah.pettibone@roswellpark.org